Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
12.25B
Market cap12.25B
Price-Earnings ratio
-35.26
Price-Earnings ratio-35.26
Dividend yield
Dividend yield
Average volume
1.90M
Average volume1.90M
High today
$75.66
High today$75.66
Low today
$73.50
Low today$73.50
Open price
$75.00
Open price$75.00
Volume
2.98M
Volume2.98M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$36.45
52 Week low$36.45

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $74.00. The company's market cap stands at 12.25B, with a P/E ratio of -35.26.

During the trading session on 2026-06-21, Ionis Pharmaceuticals(IONS) shares reached a daily high of $75.66 and a low of $73.50. At a current price of $74.00, the stock is +0.7% higher than the low and still -2.2% under the high.

Trading activity shows a volume of 2.98M, compared to an average daily volume of 1.9M.

The stock's 52-week range extends from a low of $36.45 to a high of $86.74.

The stock's 52-week range extends from a low of $36.45 to a high of $86.74.

IONS News

Simply Wall St 1d
How Olezarsen’s Longer-Term Hepatic Data and High Retention Could Shape Ionis Pharmaceuticals Investors

Earlier in June 2026, Ionis Pharmaceuticals reported positive longer-term data from its CORE-OLE extension study of olezarsen in severe hypertriglyceridemia, sh...

How Olezarsen’s Longer-Term Hepatic Data and High Retention Could Shape Ionis Pharmaceuticals Investors
TipRanks 3d
Ionis Advances ION775 Phase 2 Trial in High Triglycerides: What Investors Should Watch

Ionis Pharmaceuticals Inc. (IONS) announced an update on their ongoing clinical study. Claim 55% Off TipRanks Unlock powerful investing tools and data-driven in...

Analyst ratings

89%

of 27 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.